Notizie AIOM – anno XV – Pagina 10

24 Novembre 2017

Niraparib Approved in Europe for Ovarian Cancer

November 22, 2017 - The European Commission has approved niraparib as a maintenance therapy for women with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based ...
Leggi tutto

24 Novembre 2017

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer

Pancreatic ductal adenocarcinoma is a lethal cancer with fewer than 7% of patients surviving past 5 years. T-cell immunity has been linked to the exceptional outcome of the few long-term survivors, yet the relevant antigens remain unknown. Here we use genetic, immunohistochemical ...
Leggi tutto

24 Novembre 2017

The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIC-IV Unresectable Ovarian Cancer: Results From a Multi-Institutional Study

Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) may be a valuable treatment option in advanced ovarian cancer when primary cytoreduction is not feasible. However, a consensus on the ideal number of NACT cycles is still lacking. In the present ...
Leggi tutto

24 Novembre 2017

Web-app

Una nuova web-app gratuita, in otto lingue, per computer, tablet e smartphone sul tumore del pancreas è disponibile sul sito del Corriere della Sera in collaborazione con l'Associazione Italiana di Oncologia Medica (leggi e scarica). Strumento interattivo in due versioni, ...
Leggi tutto

21 Novembre 2017

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

Most patients with anaplastic lymphoma kinase (ALK)-rearranged or ROS proto-oncogene 1 (ROS1)-rearranged non-small-cell lung cancer (NSCLC) are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops, commonly within the CNS. This study aimed ...
Leggi tutto

21 Novembre 2017

Bevacizumab + chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial – PRODIGE 20 study results

Metastatic colorectal cancer frequently occurs in elderly patients. Bevacizumab in combination with front line chemotherapy is a standard treatment but some concern raised about tolerance of bevacizumab for these patients. The purpose of PRODIGE 20 was to evaluate tolerance ...
Leggi tutto

21 Novembre 2017

17 novembre 2017 – Domani Giornata Europea della Consapevolezza sugli Antibiotici. Le iniziative AIFA

17 Novembre 2017

17 novembre 2017 – Determinazioni AIFA n° 1821-1822 del 31/11//2017

17 Novembre 2017

15 novembre 2017 – Liste di Trasparenza

17 Novembre 2017

FDA Approves Fulvestrant in Combination With Abemaciclib in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

November 15, 2017 - Today, the U.S. Food and Drug Administration (FDA) approved a new indication for fulvestrant, expanding the drug's approved use to include combined therapy with abemaciclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, for the treatment of hormone receptor–positive, ...
Leggi tutto

LAVORIAMO CON

News

TUMORE AL SENO: METASTASI SI DIFFONDONO COME GOCCE SU UNA SUPERFICIE. LA CAPACITÀ INVASIVA DIPENDE DALLA “FLUIDITÀ” DEL CANCRO

ONE HEALTH FOUNDATION: AL VIA IL PROGETTO IN 36 CENTRI ESTIVI IN ALBANIA. SULLA “NAVE DELLA SALUTE” SVOLTI PIU’ DI 550 TEST E VISITE MEDICHE

AL VIA LA TERZA EDIZIONE DELLA “NAVE DELLA SALUTE” ITALIA-ALBANIA. LA PREVENZIONE SALE A BORDO CON 17 MEDICI SPECIALISTI E 10 AMBULATORI

TOVORAFENIB È LA PRIMA TERAPIA MIRATA APPROVATA IN EUROPA NEL GLIOMA PEDIATRICO DI BASSO GRADO RECIDIVATO O REFRATTARIO, INDIPENDENTEMENTE DAL TIPO DI ALTERAZIONE DI BRAF

TOZORAKIMAB HA SODDISFATTO L’ENDPOINT PRIMARIO DELLO STUDIO DI FASE III MIRANDA NEI PAZIENTI CON BPCO

MIASTENIA GRAVIS, 15MILA PERSONE COLPITE IN ITALIA. “UN’INSTALLAZIONE IMMERSIVA PER COMPRENDERE LA VITA DEI PAZIENTI E AUMENTARE LA CONSAPEVOLEZZA”

MELANOMA, IN ITALIA POSSONO ESSERE “EREDITARI” 2.600 CASI L’ANNO. IMI: “LA PREVENZIONE SIA ANCHE ESAMI GENETICI E SORVEGLIANZA CUTANEA”

Notizie AIOM – anno XV

Niraparib Approved in Europe for Ovarian Cancer

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer

The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIC-IV Unresectable Ovarian Cancer: Results From a Multi-Institutional Study

Web-app

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

Bevacizumab + chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial – PRODIGE 20 study results

17 novembre 2017 – Domani Giornata Europea della Consapevolezza sugli Antibiotici. Le iniziative AIFA

17 novembre 2017 – Determinazioni AIFA n° 1821-1822 del 31/11//2017

15 novembre 2017 – Liste di Trasparenza

FDA Approves Fulvestrant in Combination With Abemaciclib in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer